The Top 5 Biosimilars Articles for the Week of July 22

The Center for Biosimilars® recaps the top stories for the week of July 22, 2019.

Transcript

Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 22, 2019.

Number 5: Sandoz announced that it has enrolled its first patient in a study of a proposed biosimilar, GP2411.

Number 4: The European Medicines Agency will review Samsung Bioepis’ proposed biosimilar, SB8.

Number 3: A new paper argues that regulators should affirm the interchangeability of approved biosimilars.

Number 2: The FDA approved its fourth adalimumab biosimilar on Tuesday.

Number 1: Also on Tuesday, the FDA approved its second rituximab biosimilar.

Finally, last week, our e-newsletter asked whether you think that advocacy groups will play a role in US biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD
Julie M. Reed
Gillian Woollett, MA, Dphil
Julie M. Reed
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Related Content
© 2023 MJH Life Sciences

All rights reserved.